A new B cell differentiation antigen (BDA) on normal and leukemic human B lymphocytes that is distinct from known DR (Ia-like) antigens.
A newly defined human B cell differentiation antigen, designated as BDA, has been defined and partially characterized. BDA is expressed on normal human B cells and lymphocytic leukemia cells at all stages of known differentiation (pre-B cells to plasma cells). It is distinct from DR (Ia-like) determinants and other known B cell surface constituents.
D000818:Animals; D000918:Antibody Specificity; D000941:Antigens; D001402:B-Lymphocytes / Q000276:immunology*; D001665:Binding Sites; D002417:Cattle; D003176:Complement C3; D005455:Fluorescent Antibody Technique; D006680:HLA Antigens; D000882:Haplorhini; D006649:Histocompatibility Antigens; D006801:Humans; D007106:Immune Sera / Q000494:pharmacology; D007141:Immunoglobulin Fc Fragments; D016403:Lymphoma, Large B-Cell, Diffuse / Q000276:immunology*; D008253:Macaca mulatta; D011817:Rabbits; D011947:Receptors, Antigen, B-Cell
D000941:Antigens; D003176:Complement C3; D006680:HLA Antigens; D006649:Histocompatibility Antigens; D007106:Immune Sera; D007141:Immunoglobulin Fc Fragments; D011947:Receptors, Antigen, B-Cell